← Human Trials & Peer-Reviewed Studies
Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans.
Plain-language guide to PMID 30268384 (2019): randomized controlled trial of Glucagon.
Key Facts
- PMID
- 30268384
- Journal
- International journal of cardiology
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Verouhis D et al. (6 authors)
- DOI
- 10.1016/j.ijcard.2018.09.061
What This Study Did, in Plain Language
What Was Tested
Researchers studied Glucagon in this randomized controlled trial publication.
In the present study the researchers aimed to investigate whether the protective effect of RIC is mediated by a GLP-1 receptor-dependent mechanism in humans.
Why It Was Studied
Remote ischemic conditioning (RIC), i.e. short cycles of ischemia and reperfusion in remote tissue, is a novel approach to protect against myocardial ischemia-reperfusion injury in ST-elevation myocardial infarction.
The nature of the factors transmitting the protective effect of RIC remains unknown, and both neuronal and hormonal mechanisms appear to be involved.
Who Took Part
PubMed indexes the participants as adults, men only.
Endothelial function was determined from flow-mediated dilatation (FMD) of the brachial artery before and after 20 min of forearm ischemia and 20 min of reperfusion in twelve healthy subjects on three occasions: (A) ischemia-reperfusion without intervention, (B) ischemia-reperfusion + RIC and (C) iv administration of the GLP-1 receptor antagonist exendin(9-39) + ischemia-reperfusion + RIC.
How the Study Was Run
The design is described as randomized.
The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.
What Was Measured
PubMed files the paper under topics including Brachial Artery, Endothelium, Vascular, Glucagon-Like Peptide-1 Receptor, Healthy Volunteers, Ischemic Preconditioning, Myocardial, Myocardial Reperfusion Injury and Peptide Fragments.
Author keywords: Cardioprotection, Endothelial function, Flow-mediated dilatation, Ischemia-reperfusion and Remote ischemic conditioning.
What This Means in Plain Language
The paper is a randomized study of Glucagon.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2019 (International journal of cardiology), a journal based in Netherlands.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.